AlloVir, Inc. (NASDAQ: ALVR) is a clinical-stage biopharmaceutical company specializing in off-the-shelf, memory T-cell therapies to prevent and treat life-threatening viral infections in immunocompromised patients. Founded in 2020 and headquartered in Boston, Massachusetts, AlloVir’s approach leverages a proprietary library of antigen-specific T cells sourced from healthy donors. The company’s platform is designed to address unmet needs in transplant medicine, where viral complications such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus can lead to significant morbidity and mortality.
At the core of AlloVir’s technology is a GMP-compliant manufacturing process that enables rapid identification, enrichment and cryopreservation of virus-specific memory T cells. This allogeneic T-cell library serves as a foundation for both monovalent and multivalent products. The lead candidate, ALVR105, targets CMV in allogeneic hematopoietic stem cell transplant recipients and has advanced into pivotal clinical trials. Additional pipeline programs include therapies against EBV-associated complications and adenoviral infections, reflecting the platform’s versatility.
AlloVir collaborates with academic centers, research institutions and regulatory agencies to optimize trial design and ensure broad access to its therapies. The company has established partnerships in North America and Europe, aiming to secure global supply chains and regulatory approvals. Manufacturing takes place in the United States, with plans for future capacity expansion to support late-stage development and eventual commercialization.
Led by Chief Executive Officer Kenneth Berlin, AlloVir’s management team brings deep expertise in cell therapy, infectious disease and commercial strategy. The company’s board and scientific advisory council include leaders in immunology and transplant medicine, guiding clinical development and regulatory interactions. As AlloVir progresses through pivotal trials, it seeks to offer hospitals and transplant centers a novel therapeutic option for high-risk patients facing viral complications.
AI Generated. May Contain Errors.
